Calculating utility: preclinical evidence for cost-benefit analysis by mesolimbic dopamine

Paul E M Phillips1, Mark E Walton, Thomas C Jhou

  • 1Department of Psychiatry and Behavioral Sciences, University of Washington, P.O. Box 356560, Seattle, WA, 98195-6560, USA. pemp@u.washington.edu

Psychopharmacology
|November 23, 2006
PubMed
Abstract

Related Concept Videos